Our results recapitulate some of these findings and validate SEL120-34A as a strong inhibitor of proliferation in AML cell lines, both in vitro and in vivo. The complex nature of these effects is evident given the significant differences in cell lines sensitivity between CA and the three other type I CDK8 inhibitors used in this study. Here, CDK8 is linked to acute myeloid leukemia.